Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Article in English | MEDLINE | ID: mdl-38664888

ABSTRACT

BACKGROUND: The efficacy and safety of adjunctive low-voltage area (LVA) ablation on outcomes of catheter ablation (CA) for atrial fibrillation (AF) remains uncertain. METHODS: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) comparing CA with versus without LVA ablation for patients with AF. Risk ratios (RR) with 95% confidence intervals (CI) were pooled with a random-effects model. Our primary endpoint was recurrence of atrial tachyarrhythmia (ATA), including AF, atrial flutter, or atrial tachycardia. We used R version 4.3.1 for all statistical analyses. RESULTS: Our meta-analysis included 10 RCTs encompassing 1780 patients, of whom 890 (50%) were randomized to LVA ablation. Adjunctive LVA ablation significantly reduced recurrence of ATA (RR 0.76; 95% CI 0.67-0.88; p < .01) and reduced the number of redo ablation procedures (RR 0.54; 95% CI 0.35-0.85; p < .01), as compared with conventional ablation. Among 691 (43%) patients with documented LVAs on baseline substrate mapping, adjunctive LVA ablation substantially reduced ATA recurrences (RR 0.57; 95% CI 0.38-0.86; p < .01). There was no significant difference between groups in terms of periprocedural adverse events (RR 0.78; 95% CI 0.39-1.56; p = .49). CONCLUSIONS: Adjunctive LVA ablation is an effective and safe strategy for reducing recurrences of ATA among patients who undergo CA for AF.

2.
J Cardiothorac Vasc Anesth ; 38(3): 649-659, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38228424

ABSTRACT

OBJECTIVE: To verify the impact of preoperative levosimendan on patients with severe left ventricular dysfunction (ejection fraction <35%) undergoing isolated coronary artery bypass grafting. DESIGN: A meta-analysis. SETTING: Hospitals. PARTICIPANTS: The authors included 1,225 patients from 6 randomized controlled trials. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The authors performed a meta-analysis of trials that compared preoperative levosimendan with placebo or no therapy, reporting efficacy and safety endpoints. Statistical analyses used mean differences and risk ratios (RR), with a random effects model. Six studies were included, comprising 1,225 patients, of whom 615 (50.2%) received preoperative levosimendan, and 610 (49.8%) received placebo/no therapy. Preoperative levosimendan showed a lower risk of all-cause mortality (RR 0.31; 95% CI 0.16-0.60; p < 0.01; I2 = 0%), postoperative acute kidney injury (RR 0.44; 95% CI 0.25-0.77; p < 0.01; I2 = 0%), low-cardiac-output syndrome (RR 0.45; 95% CI 0.30-0.66; p < 0.001; I2 = 0%), and postoperative atrial fibrillation (RR 0.49; 95% CI 0.25-0.98; p = 0.04; I2 = 85%) compared to control. Moreover, levosimendan significantly reduced the need for postoperative inotropes and increased the cardiac index at 24 hours postoperatively. There were no differences between groups for perioperative myocardial infarction, hypotension, or any adverse events. CONCLUSION: Preoperative levosimendan in patients with severe left ventricular dysfunction undergoing isolated coronary artery bypass grafting was associated with reduced all-cause mortality, low-cardiac-output syndrome, acute kidney injury, postoperative atrial fibrillation, and the need for circulatory support without compromising safety.


Subject(s)
Acute Kidney Injury , Atrial Fibrillation , Simendan , Ventricular Dysfunction, Left , Humans , Acute Kidney Injury/etiology , Atrial Fibrillation/etiology , Cardiac Output, Low/drug therapy , Cardiac Output, Low/etiology , Cardiotonic Agents/therapeutic use , Coronary Artery Bypass/adverse effects , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , Postoperative Complications/drug therapy , Randomized Controlled Trials as Topic , Simendan/therapeutic use
3.
Can J Anaesth ; 2023 Oct 11.
Article in English | MEDLINE | ID: mdl-37821677

ABSTRACT

PURPOSE: Total knee arthroplasty (TKA) is associated with severe postoperative pain. Continuous adductor canal blockade provides analgesia while preserving quadriceps muscle strength. Nevertheless, uncertainty still exists as to the optimal adductor canal catheter placement approach. We sought to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the analgesic effects of proximal vs distal adductor canal catheters in patients undergoing TKA. SOURCE: We systematically searched PubMed, EMBASE, and Cochrane for RCTs comparing distal and proximal adductor canal catheters for TKA regarding critical clinical outcomes in adult patients. Statistical analysis was performed using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity was assessed using the Cochran Q test and I2 statistics. Trial sequential analysis (TSA) was performed to evaluate the risk of random errors and the uncertainty of our results. The risk of bias was appraised according to the RoB-2 tool. PRINCIPAL FINDINGS: Six RCTs and 352 patients were included, of whom 151 (42.9%) were male, and 175 (49.7%) were randomized to undergo proximal adductor canal catheter placement. Due to the randomized nature of the studies, baseline characteristics were similar between groups. There were no statistical differences between proximal and distal adductor canal catheters regarding cumulative opioid consumption in the first 24 hr (mean difference [MD], -4.86; 95% confidence interval [CI], -15.19 to 5.47; P = 0.36; four RCTs; 240 patients); pain scores at rest (MD, 0.41; 95% CI, -1.23 to 0.40; P = 0.32; six RCTs; 350 patients); and pain scores with movement for the first 24 hr (MD, -0.25; 95% CI, -0.85 to 0.35; P = 0.42; four RCTs; 246 patients). In the TSA, the required information size was not reached, and the Z-curve did not cross the monitoring boundaries in any of the endpoints. CONCLUSION: These findings suggest that proximal vs distal adductor canal catheter placement in patients undergoing TKA may be equally effective for the outcomes of opioid consumption in the first 24 hr, pain scores at rest, and pain scores with movement in the first 24 hr. Nevertheless, TSA findings suggest insufficient power to definitively conclude no differences between the two techniques. STUDY REGISTRATION: PROSPERO (CRD42022353576); registered 25 August 2022.


RéSUMé: OBJECTIF: L'arthroplastie totale du genou (ATG) est associée à une douleur postopératoire majeure. Le bloc continu du canal adducteur procure une analgésie tout en préservant la force musculaire du quadriceps. Néanmoins, il existe encore des incertitudes quant à l'approche optimale de positionnement du cathéter du canal adducteur. Nous avons cherché à réaliser une revue systématique et une méta-analyse d'études randomisées contrôlées (ERC) comparant les effets analgésiques de cathéters proximaux et distaux du canal adducteur chez la patientèle bénéficiant d'une ATG. SOURCES: Nous avons réalisé des recherches systématiques dans les bases de données PubMed, EMBASE et Cochrane pour en tirer les ERC comparant les cathéters distaux et proximaux du canal adducteur pour l'ATG touchant aux critères d'évaluation cliniques critiques chez les patient·es adultes. L'analyse statistique a été réalisée à l'aide de la version R 4.1.2 (R Foundation for Statistical Computing, Vienne, Autriche). L'hétérogénéité a été évaluée à l'aide du test Q de Cochran et des statistiques I2. Une analyse séquentielle des études a été réalisée pour évaluer le risque d'erreurs aléatoires et l'incertitude de nos résultats. Le risque de biais a été évalué selon l'outil RoB-2. CONSTATATIONS PRINCIPALES: Six ERC et 352 patient·es ont été inclus·es, dont 151 (42,9 %) hommes, et 175 (49,7 %) ont été randomisé·es pour bénéficier d'une pose proximale d'un cathéter du canal adducteur. En raison de la nature randomisée des études, les caractéristiques initiales étaient similaires entre les groupes. Il n'y avait aucune différence statistique entre les cathéters proximaux et distaux du canal adducteur en ce qui concerne la consommation cumulative d'opioïdes au cours des premières 24 heures (différence moyenne [DM], −4,86; intervalle de confiance [IC] à 95 %, −15,19 à 5,47; P = 0,36; quatre ERC; 240 patient·es); les scores de douleur au repos (DM, −0,41; IC 95 %, −1,23 à 0,40; P = 0,32; six ERC ; 350 patient·es); et les scores de douleur en mouvement pendant les premières 24 heures (DM, −0,25; IC 95 %, −0,85 à 0,35; P = 0,42; quatre ERC; 246 patient·es). Dans l'analyse séquentielle des études, la taille d'information requise n'a pas été atteinte et la courbe en Z n'a franchi les limites de surveillance dans aucun des paramètres. CONCLUSION: Ces résultats suggèrent que le positionnement proximal ou distal d'un cathéter du canal adducteur chez les personnes subissant une ATG peut être tout aussi efficace en ce qui touche aux critères de consommation d'opioïdes au cours des premières 24 heures, de scores de douleur au repos et de scores de douleur en mouvement au cours des premières 24 heures. Néanmoins, les résultats de l'analyse séquentielle suggèrent une puissance insuffisante pour conclure de manière définitive à l'absence de différences entre les deux techniques. ENREGISTREMENT DE L'éTUDE: PROSPERO (CRD42022353576); enregistrée le 25 août 2022.

4.
J Am Coll Cardiol ; 82(18): 1765-1773, 2023 10 31.
Article in English | MEDLINE | ID: mdl-37611779

ABSTRACT

BACKGROUND: The optimal antithrombotic therapy following left atrial appendage occlusion (LAAO) in patients with nonvalvular atrial fibrillation (AF) remains uncertain. OBJECTIVES: In this study, the authors sought to compare the efficacy and safety of various antithrombotic strategies after LAAO. METHODS: We searched the Medline, Cochrane, EMBASE, LILACS, and ClinicalTrials.gov databases for studies reporting outcomes after LAAO, stratified by antithrombotic therapy prescribed at postprocedural discharge. Direct oral anticoagulants (DOACs), vitamin K antagonists (VKAs), single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT), DOAC plus SAPT, VKA plus SAPT, and no antithrombotic therapy were analyzed. We performed a frequentist random effects model network meta-analysis to estimate the OR and 95% CI for each comparison. P-scores provided a ranking of treatments. RESULTS: Forty-one studies comprising 12,451 patients with nonvalvular AF were included. DAPT, DOAC, DOAC plus SAPT, and VKA were significantly superior to no therapy to prevent device-related thrombosis. DOAC was associated with lower all-cause mortality than VKA (OR: 0.39; 95% CI: 0.17-0.89; P = 0.03). Compared with SAPT, DAPT was associated with fewer thromboembolic events (OR: 0.50; 95% CI: 0.29-0.88; P = 0.02), without a difference in major bleeding. In the analysis of P-scores, DOAC monotherapy was the strategy most likely to have lower thromboembolic events and major bleeding. CONCLUSIONS: In this network meta-analysis comparing initial antithrombotic therapies after LAAO, monotherapy with DOAC had the highest likelihood of lower thromboembolic events and major bleeding. DAPT was associated with a lower incidence of thromboembolic events compared with SAPT and may be a preferred option in patients unable to tolerate anticoagulation.


Subject(s)
Atrial Appendage , Atrial Fibrillation , Stroke , Thromboembolism , Humans , Platelet Aggregation Inhibitors , Fibrinolytic Agents/therapeutic use , Atrial Appendage/surgery , Network Meta-Analysis , Anticoagulants , Hemorrhage/etiology , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Thromboembolism/epidemiology , Thromboembolism/etiology , Thromboembolism/prevention & control , Stroke/etiology , Treatment Outcome
5.
Clin Res Cardiol ; 112(7): 991-1002, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37140823

ABSTRACT

BACKGROUND: Hyperkalemia leads to suboptimal use of evidence-based therapies in patients with heart failure (HF). Therefore, we aimed to assess whether new potassium binders are effective and safe to promote medical optimization in patients with HF. METHODS: MEDLINE, Cochrane, and Embase were searched for randomized controlled trials (RCTs) that reported outcomes after initiation of Patiromer or Sodium Zirconium Cyclosilicate (SZC) versus placebo in patients with HF at high risk of hyperkalemia development. Risk ratios (RR) with 95% confidence intervals (CI) were pooled with a random effects model. Quality assessment and risk of bias were performed according to Cochrane recommendations. RESULTS: A total of 1432 patients from 6 RCTs were included, of whom 737 (51.5%) patients received potassium binders. In patients with HF, potassium binders increased the use of renin-angiotensin-aldosterone inhibitors (RR 1.14; 95% CI 1.02-1.28; p = 0.021; I2 = 44%) and reduced the risk of hyperkalemia (RR 0.66; 95% CI 0.52-0.84; p < 0.001; I2 = 46%). The risk of hypokalemia was significantly increased in patients treated with potassium binders (RR 5.61; 95% CI 1.49-21.08; p = 0.011; I2 = 0%). There was no difference between groups in all-cause mortality rates (RR 1.13; 95% CI 0.59-2.16; p = 0.721; I2 = 0%) or in adverse events leading to drug discontinuation (RR 1.08; 95% CI 0.60-1.93; p = 0.801; I2 = 0%). CONCLUSION: The use of new potassium binders Patiromer or SZC in patients with HF at risk for hyperkalemia increased the rates of medical therapy optimization with renin-angiotensin-aldosterone inhibitors and reduced the incidence of hyperkalemia, at the cost of an increased prevalence of hypokalemia.


Subject(s)
Heart Failure , Hyperkalemia , Hypokalemia , Humans , Hyperkalemia/drug therapy , Hyperkalemia/etiology , Potassium , Hypokalemia/complications , Renin/pharmacology , Renin/therapeutic use , Aldosterone/pharmacology , Aldosterone/therapeutic use , Randomized Controlled Trials as Topic , Heart Failure/complications , Heart Failure/drug therapy , Renin-Angiotensin System , Mineralocorticoid Receptor Antagonists/therapeutic use , Angiotensins/pharmacology , Angiotensins/therapeutic use
6.
Clin Res Cardiol ; 112(8): 1044-1055, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36592186

ABSTRACT

BACKGROUND: We sought to compare cardiovascular outcomes, renal function, and diuresis in patients receiving standard diuretic therapy for acute heart failure (AHF) with or without the addition of SGLT2i. METHODS AND RESULTS: Systematic search of three electronic databases identified nine eligible randomized controlled trials involving 2,824 patients. The addition of SGLT2i to conventional therapy for AHF reduced all-cause death (odds ratio [OR] 0.75; 95% CI 0.56-0.99; p = 0.049), readmissions for heart failure (HF) (OR 0.54; 95% CI 0.44-0.66; p < 0.001), and the composite of cardiovascular death and readmissions for HF (hazard ratio 0.71; 95% CI 0.60-0.84; p < 0.001). Furthermore, SGLT2i increased mean daily urinary output in liters (mean difference [MD] 0.45; 95% CI 0.03-0.87; p = 0.035) and decreased mean daily doses of loop diuretics in mg of furosemide equivalent (MD -34.90; 95% CI [- 52.58, - 17.21]; p < 0.001) without increasing the incidence worsening renal function (OR 0.75; 95% CI 0.43-1.29; p = 0.290). CONCLUSION: SGLT2i addition to conventional diuretic therapy reduced all-cause death, readmissions for HF, and the composite of cardiovascular death or readmissions for HF. Moreover, SGLT2i was associated with a higher volume of diuresis with a lower dose of loop diuretics.


Subject(s)
Diabetes Mellitus, Type 2 , Heart Failure , Sodium-Glucose Transporter 2 Inhibitors , Humans , Diabetes Mellitus, Type 2/complications , Diuretics/adverse effects , Diuretics/pharmacology , Diuretics/therapeutic use , Heart Failure/drug therapy , Kidney/drug effects , Randomized Controlled Trials as Topic , Sodium Potassium Chloride Symporter Inhibitors , Sodium-Glucose Transporter 2 Inhibitors/adverse effects , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
7.
Pediatr Surg Int ; 39(1): 63, 2022 Dec 25.
Article in English | MEDLINE | ID: mdl-36574093

ABSTRACT

PURPOSE: To investigate if Antibiotic Prophylaxis (AP) can prevent wound and/or systemic infection in pediatric patients who underwent Percutaneous Endoscopic Gastrostomy (PEG). METHODS: PubMed, Embase, and Cochrane databases were searched for Randomized Controlled Trials (RCT) and Observational Studies that compared AP vs. no Intervention (NI) in children submitted to PEG. Odds ratios (OR) with 95% confidence intervals (CI) were pooled with random-effect models. Quality assessment and risk of bias were performed as outlined by Cochrane recommendations. RESULTS: Four studies, including one RCT, with a total of 568 patients were included, in which 230 (40.5%) individuals received AP. The use of AP during PEG reduced the incidence of systemic infection (OR 0.46; 95% CI 0.24-0.90; p = 0.02; I2 = 0). However, no statistical difference was found for wound infection (OR 0.85; 95% CI 0.43-1.69; p = 0.64; I2 = 12%) and for the composite outcome of any kind of infection (OR 0.74; 95% CI 0.13-4.06; p = 0.73; I2 = 67%). CONCLUSION: In this pooled analysis of 568 infants who underwent PEG, the use of AP reduced the incidence of systemic infection. Our results were compatible with findings obtained in the adult population. No differences were found regarding wound infection or the composite outcome of any kind of infection.


Subject(s)
Antibiotic Prophylaxis , Sepsis , Infant , Adult , Humans , Child , Antibiotic Prophylaxis/methods , Gastrostomy/methods , Surgical Wound Infection/epidemiology , Surgical Wound Infection/prevention & control , Surgical Wound Infection/etiology , Incidence , Anti-Bacterial Agents/therapeutic use
8.
J Card Surg ; 37(12): 4646-4653, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36259716

ABSTRACT

BACKGROUND: The efficacy and safety of percutaneous coronary interventions (PCI) relative to coronary artery bypass grafting (CABG) in patients with diabetes and unprotected left main coronary artery disease (LMCAD) are not well established. OBJECTIVES: To perform a meta-analysis evaluating the long-term outcomes after PCI with drug-eluting stents (DES), as compared with CABG, in patients with diabetes and unprotected LMCAD. METHODS: MEDLINE, Cochrane, and Embase were searched for randomized controlled trials (RCTs) that reported outcomes after PCI with DES versus CABG in unprotected LMCAD among patients with diabetes. To evaluate the long-term effects of these interventions, we restricted this analysis to studies with a minimum follow-up period of 3 years. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled with a random-effects model. Quality assessment and risk of bias were performed according to Cochrane recommendations. RESULTS: Four RCTs with a total of 1080 patients were included, 553 (51.2%) of whom underwent PCI. There was no difference for individual outcomes of all-cause mortality (RR: 1.21; 95% CI: 0.86-1.71; p = .27; I2 = 28%), cardiovascular death (RR 1.29; 95% CI: 0.76-2.18; p = .34; I2 = 0%), or myocardial infarction (MI) (RR: 0.94; 95% CI: 0.61-1.45; p = .79; I2 = 0%). However, the risk of stroke was reduced with PCI relative to CABG (RR: 0.41; 95% CI: 0.18-0.94; p = .04; I2 = 0%), whereas the risk of any repeat revascularization was higher in the PCI group (RR: 1.99; 95% CI: 1.44-2.75; p < .001; I2 = 0%). The risk of the composite outcome of all-cause mortality, MI, stroke, or repeat revascularization was higher after PCI compared with CABG (RR: 1.30; 95% CI: 1.09-1.56; p = .004; I2 = 0%). CONCLUSION: In this meta-analysis with more than 1000 patients with diabetes and unprotected LMCAD followed for a minimum of 3 years, the incidence of repeat revascularization was higher among those treated with PCI, whereas the risk of stroke was higher in patients treated with CABG.


Subject(s)
Coronary Artery Disease , Diabetes Mellitus , Drug-Eluting Stents , Myocardial Infarction , Percutaneous Coronary Intervention , Stroke , Humans , Coronary Artery Disease/complications , Coronary Artery Disease/surgery , Drug-Eluting Stents/adverse effects , Treatment Outcome , Randomized Controlled Trials as Topic , Myocardial Infarction/etiology , Myocardial Infarction/complications , Diabetes Mellitus/epidemiology , Percutaneous Coronary Intervention/adverse effects , Stroke/epidemiology , Stroke/etiology
9.
Adv Physiol Educ ; 46(3): 351-357, 2022 Sep 01.
Article in English | MEDLINE | ID: mdl-35549509

ABSTRACT

The COVID-19 pandemic affected almost all aspects of our lives, including the education sector and the way of teaching and learning. In March 2020, health authorities in Brazil imposed social isolation and the interruption of on-site activities in schools and universities. In this context, the Federal University of Minas Gerais (UFMG), one of the largest universities in Brazil and Latin America, developed an emergency remote learning (ERL) plan that allowed the return of classes in an online format and supported students to obtain access to equipment and internet network. Within this new perspective, the Undergraduate Teaching Assistant (UTA) program of the Department of Physiology and Biophysics (DFIB) explored strategies to minimize the impact of the absence of face-to-face classes. Using different available tools in online platforms and social media such as Microsoft Teams, YouTube animated video classes, and Instagram, the UTA program assisted >500 undergraduate students and strongly supported professors during ERL. In just over a year, our video classes on YouTube Channel reached ∼40,000 views. Most of the students reported that their questions were fully and quickly solved by the UTA program. Collectively, our results indicate that the strategies implemented by the UTA program helped the undergraduate students and professors to adapt to a remote learning format.


Subject(s)
COVID-19 , Education, Distance , Biophysics , Education, Distance/methods , Humans , Pandemics , Students
SELECTION OF CITATIONS
SEARCH DETAIL
...